Christina T. Loguidice

Articles

MCL Treatments Step Away From Chemotherapy, Closer to a Cure

April 24th 2020

During a recent OncLive Peer Exchange®, a panel of hematologic cancer experts discussed several novel treatments that are changing the relapsed/refractory mantle cell lymphoma treatment landscape, including Bruton tyrosine kinase (BTK) inhibitors, BTK combinations, and chimeric antigen receptor T-cell therapy.

Fresh Options Are Emerging for Relapsed DLBCL

April 7th 2020

Although considerable progress has been made in treating diffuse large B-cell lymphoma since the advent of chemoimmunotherapy, approximately 33% of patients still develop relapsed/refractory disease, which is associated with considerable morbidity and mortality.

Key Questions Surround CDK4/6 Inhibitors in HR+ Breast Cancer

February 28th 2020

During a recent OncLive Peer Exchange®, a panel of experts sought to answer several key questions regarding the management of advanced, hormone receptor–positive breast cancer, particularly with CDK4/6 inhibitors.

3 Keys to Prostate Cancer Care: Clarify, Classify, Personalize

February 12th 2020

The treatment paradigm for patients with prostate cancer is evolving, with the growth of approved and newly developed agents and an increased understanding of the role of genomic drivers.

Immunotherapy Opens Doors in Small Cell Lung Cancer

February 2nd 2020

Immune checkpoint inhibitors have yielded modest improvement in small cell lung cancer (SCLC), but have already reshaped the management of this tumor type and helped open the door to the exploration of other, potentially more effective treatment approaches, according to a panel of thoracic oncology experts who discussed the treatment horizon for SCLC in a recent OncLive Peer Exchange® panel.

PARP Inhibitors Gain Importance in Ovarian Cancer Lineup

January 15th 2020

PARP inhibitors are poised to acquire a stronger foothold in the frontline setting for advanced ovarian cancer, for which chemotherapy remains the backbone of treatment, according to a panel of gynecologic oncology experts who discussed the issue during an OncLive Peer Exchange® held during the European Society for Medical Oncology Congress 2019.

New BTK Agents and Combinations Are on the Horizon for B-cell Malignancies

December 5th 2019

During a recent OncLive Peer Exchange, a panel of leukemia and lymphoma experts discussed emerging BTK inhibitors.

Rapid Growth of Targeted Therapies in AML Spurs Need for More Learning

November 14th 2019

During a recent OncLive Peer Exchange® program, a panel of leukemia experts provided an overview of these agents and shared their perspectives on how clinicians can incorporate them into their clinical practice.

New Sequencing Approaches Shape Follicular Lymphoma Landscape

November 6th 2019

With a variety of available agents in follicular lymphoma, determining which treatments to choose and how best to sequence them can be challenging.

Pancreatic Cancer Is Moving Beyond the Tip of the Treatment Iceberg

October 3rd 2019

During an OncLive Peer Exchange®, a panel of pancreatic cancer experts discuss how they select between first- and subsequent-line cytotoxic regimens and strategies they use to reduce toxicity, including dose modifications and alternative combinations. They also provide insights on some of the emerging therapies in clinical trials for advanced pancreatic cancer.

Neoadjuvant and Frontline Studies Guide Malignant Melanoma Treatment

September 19th 2019

Five melanoma experts discuss findings from several exciting studies presented at the 2019 ASCO Annual Meeting that are helping to change the way patients with malignant melanoma are treated.

New and Emerging Immunotherapy Combos for Advanced RCC: Finding the Right Treatments

August 16th 2019

Emerging immunotherapy combinations have offered a strong challenge to sunitinib (Sutent) in the setting of frontline advanced clear cell renal cell carcinoma.

How CDK4/6 Inhibitors Are Shaking Up the Breast Cancer Paradigm

July 28th 2019

During a recent OncLive Peer Exchange®, a panel of breast cancer experts discussed how they are using CDK4/6 inhibitors in their practices. They shared their insights on the tolerability and toxicity profiles of the FDA-approved CDK4/6 inhibitors, how they choose which agents to use for each patient, and how they select the next line of therapy after the patient progresses.

NTRK Gene Fusions: Finding the "Golden Ticket" in Oncology

July 18th 2019

During an OncologyLive Peer Exchange, the panelists discuss some of the challenges they face when conducting molecular testing, including determining which patients to test, when to test, and how to test to ensure that no golden tickets, such as NTRK gene fusions, are missed. They also discuss the data surrounding TRK inhibitors and their experiences using these agents.

Leave No One Behind: Optimizing Targeted Therapies in Ovarian Cancer

July 1st 2019

The development of targeted therapies, including bevacizumab (Avastin) and 3 PARP inhibitors, is changing treatment paradigms for women with epithelial ovarian cancer.

Systemic Treatments for NETs: Whom to Treat and How to Sequence

May 2nd 2019

During a recent panel discussion, neuroendocrine tumor experts Simron Singh, MD, MPH, and Jonathan R. Strosberg, MD, provided insight on which patients are the best candidates for these approved treatments and how to sequence therapy to optimize outcomes.

Experts Dissect 3 Practice-Changing Studies for Newly Diagnosed CLL

April 1st 2019

During an OncLive Peer Exchange®, a panel of CLL experts review findings from studies presented at the 2018 American Society of Hematology meeting in December: iLLUMINATE, Alliance A041202, and ECOG E1912.

Novel Agents Spark New Approaches for Triple-Negative Breast Cancer

February 15th 2019

During a recent OncLive Peer Exchange®, a panel of breast cancer experts discussed emerging agents in triple-negative breast cancer, which include an anti–PD-L1 antibody, 2 PARP inhibitors, and a novel antibody–drug conjugate.

New Findings Expand Options in Early HER2-Positive Breast Cancer

February 4th 2019

During a recent OncLive Peer Exchange®, panel members discussed the use of HER2-targeted therapies in patients with early-stage HER2-positive breast cancer in the neoadjuvant and adjuvant settings.

Evidence Grows for Earlier Immunotherapy in NSCLC

January 24th 2019

Clinical trial evidence is building for moving checkpoint blockade immunotherapy forward in the treatment timeline for non–small cell lung cancer, but improving patient selection for these therapies remains a key challenge.